

National Veterinary Clinicians Group

**Annual Financial Statements
for the year ended 31 December 2023**

Independently Reviewed Financial Statements

in compliance with the Companies Act of South Africa

National Veterinary Clinicians Group

Annual Financial Statements for the year ended 31 December 2023

Index

	Page
General Information	2
Report of the Independent Reviewer	3 - 4
Directors' Responsibilities and Approval	5
Directors' Report	6
Statement of Financial Position	7
Statement of Comprehensive Income	8
Statement of Changes in Equity	9
Statement of Cash Flows	10
Accounting Policies	11 - 12
Notes to the Financial Statements	13
Supplementary information: Detailed Income Statement	14

National Veterinary Clinicians Group

Annual Financial Statements for the year ended 31 December 2023

General Information

Country of Incorporation and Domicile	South Africa
Nature of Business and Principal Activities	The company is in the promotion of the interest of veterinary clinicians.
Directors	Dr Dave Miller Dr Jono Savadier Dr Richard Smith
Registered Office	62 Herbert Baker Street Groenkloof Pretoria Gauteng 0181
Business Address	62 Herbert Baker Street Groenkloof Pretoria Gauteng 0181
Postal Address	P.O. Box 845 Ballito 4420
Bankers	First National Bank Limited
Professional Accountants	Abacus At Work Review Services 538 Lois Avenue Erasmuskloof Pretoria Gauteng 0181
Preparer	Abacus At Work Review Services 538 Lois Avenue Erasmuskloof Pretoria Gauteng 0181

Abacus huis
Lois Avenue 538
Erasmuskloof
0181
Pretoria

Abacus House
Lois Avenue 538
Erasmuskloof
0181
Pretoria

Tel: 012 342
3736
Fax: 012 342 1503

PO Box 13190
Hatfield
0028

Date:

Our ref.:

Your ref.:

Report of the Independent Reviewer

To the Shareholder of National Veterinary Clinicians Group

We have reviewed the financial statements of National Veterinary Clinicians Group set out on pages 7 to 13, which comprise the statement of financial position as at 31 December 2023, and the statement of comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

Directors' Responsibility for the Annual Financial Statements

The directors are responsible for the preparation and fair presentation of these financial statements in accordance with the IFRS for SMEs Accounting Standard as issued by the International Accounting Standards Board and the requirements of the Companies Act of South Africa, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Independent Reviewer's Responsibility

Our responsibility is to express a conclusion on these financial statements. We conducted our review in accordance with the International Standard on Review Engagements (ISRE) 2400 (Revised), Engagements to Review Historical Financial Statements (ISRE 2400 (Revised)). ISRE 2400 (Revised) requires us to conclude whether anything has come to our attention that causes us to believe that the financial statements, taken as a whole, are not prepared in all material respects in accordance with the applicable financial reporting framework. This Standard also requires us to comply with relevant ethical requirements.

A review of financial statements in accordance with ISRE 2400 (Revised) is a limited assurance engagement. The independent reviewer performs procedures, primarily consisting of making inquiries of management and others within the entity, as appropriate, and applying analytical procedures, and evaluates the evidence obtained.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with International Standards on Auditing. Accordingly, we do not express an audit opinion on these financial statements.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that these financial statements do not present fairly, in all material respects, the financial position of National Veterinary Clinicians Group as at 31 December 2023, and its financial performance and cash flows for the year then ended in accordance with the IFRS for SMEs Accounting Standard as issued by the International Accounting Standards Board and the requirements of the Companies Act of South Africa.

Basis of Accounting

Without modifying our conclusion, we draw attention to note 2 to the financial statements, which describes the basis of accounting. The financial statements are prepared in accordance with the company's own accounting policies to satisfy the financial information needs of the company's shareholders. As a result, the financial statements may not be suitable for another purpose.

Abacus At Work Review Services

6 August 2024



Per: Deale, Johannes Jacobus

Partner

Professional Accountant

538 Lois Avenue

Erasmuskloof

Pretoria

Gauteng

0181

National Veterinary Clinicians Group

Annual Financial Statements for the year ended 31 December 2023

Directors' Responsibilities and Approval

The directors are required by the Companies Act of South Africa to maintain adequate accounting records and are responsible for the content and integrity of the annual financial statements and related financial information included in this report. These annual financial statements have been prepared in accordance with the IFRS for SMEs[®] Accounting Standard as issued by the International Accounting Standards Board (IASB[®]) and it is their responsibility to ensure that the annual financial statements satisfy the financial reporting standards with regards to form and content and present fairly the statement of financial position, results of operations and business of the company, and explain the transactions and financial position of the business of the company at the end of the financial year. The annual financial statements are based upon appropriate accounting policies consistently applied throughout the company and supported by reasonable and prudent judgements and estimates.

The directors acknowledge that they are ultimately responsible for the system of internal financial control established by the company and place considerable importance on maintaining a strong control environment. To enable the directors to meet these responsibilities, the directors set standards for internal control aimed at reducing the risk of error or loss in a cost effective manner. The standards include the proper delegation of responsibilities within a clearly defined framework, effective accounting procedures and adequate segregation of duties to ensure an acceptable level of risk. These controls are monitored throughout the company and all employees are required to maintain the highest ethical standards in ensuring the company's business is conducted in a manner that in all reasonable circumstances is above reproach.

The focus of risk management in the company is on identifying, assessing, managing and monitoring all known forms of risk across the company. While operating risk cannot be fully eliminated, the company endeavours to minimise it by ensuring that appropriate infrastructure, controls, systems and ethical behaviour are applied and managed within predetermined procedures and constraints.

The directors are of the opinion, based on the information and explanations given by management, that the system of internal control provides reasonable assurance that the financial records may be relied on for the preparation of the annual financial statements. However, any system of internal financial control can provide only reasonable, and not absolute, assurance against material misstatement or loss. The going-concern basis has been adopted in preparing the financial statements. Based on forecasts and available cash resources the directors have no reason to believe that the company will not be a going concern in the foreseeable future. The annual financial statements support the viability of the company.

Dr Dave Miller

Dr Jono Savadier

Dr Richard Smith

National Veterinary Clinicians Group

Annual Financial Statements for the year ended 31 December 2023

Directors' Report

The directors present their report for the year ended 31 December 2023.

1. Review of activities

Main business and operations

The company is in the promotion of the interest of veterinary clinicians. There were no major changes herein during the year.

The operating results and statement of financial position of the company are fully set out in the attached financial statements and do not in our opinion require any further comment.

2. Going concern

The annual financial statements have been prepared on the basis of accounting policies applicable to a going concern. This basis presumes that funds will be available to finance future operations and that the realisation of assets and settlement of liabilities, contingent obligations and commitments will occur in the ordinary course of business.

3. Events after reporting date

All events subsequent to the date of the annual financial statements and for which the applicable financial reporting framework requires adjustment or disclosure have been adjusted or disclosed.

The directors are not aware of any matter or circumstance arising since the end of the financial year to the date of this report that could have a material effect on the financial position of the company.

4. Authorised and issued share capital

No changes were approved or made to the authorised or issued share capital of the company during the year under review.

5. Dividend

No dividend was declared or paid to the shareholder during the year.

6. Directors

The directors of the company during the year and up to the date of this report are as follows:

Dr Dave Miller

Dr Jono Savadier

Dr Richard Smith

7. Shareholder

There have been no changes in ownership during the current financial year.

The shareholder and its interest at the end of the year is:

8. Independent Reviewers

Abacus At Work Review Services were the independent reviewers for the year under review.

National Veterinary Clinicians Group

Financial Statements for the year ended 31 December 2023

Statement of Financial Position

Figures in R

Notes

2023

2022

Assets

Current assets

Trade and other receivables

4 193,314 90,580

Cash and cash equivalents

5 1,349,202 1,369,720

Total current assets

1,542,516 1,460,300

Total assets

1,542,516 1,460,300

Equity and liabilities

Equity

Retained income

1,404,034 1,336,199

Liabilities

Current liabilities

Trade and other payables

6 138,482 124,101

Total equity and liabilities

1,542,516 1,460,300

National Veterinary Clinicians Group

Financial Statements for the year ended 31 December 2023

Statement of Comprehensive Income

Figures in R

	Note	2023	2022
Revenue	7	173,436	169,355
Other expenses		(194,325)	(177,686)
Loss from operating activities		(20,889)	(8,331)
Finance income		88,724	43,172
Profit for the year		67,835	34,841

National Veterinary Clinicians Group

Financial Statements for the year ended 31 December 2023

Statement of Changes in Equity

Figures in R	Retained income
Balance at 1 January 2022	1,301,358
Changes in equity	
Profit for the year	34,841
Total comprehensive income for the year	34,841
Balance at 31 December 2022	1,336,199
Balance at 1 January 2023	1,336,199
Changes in equity	
Profit for the year	67,835
Total comprehensive income for the year	67,835
Balance at 31 December 2023	1,404,034

National Veterinary Clinicians Group

Financial Statements for the year ended 31 December 2023

Statement of Cash Flows

Figures in R

Note 2023 2022

	Note	2023	2022
Cash flows used in operations			
Profit for the year		67,835	34,841
Adjustments to reconcile profit			
Adjustments for finance income		(88,724)	(43,172)
Adjustments for decrease / (increase) in trade accounts receivable		10,016	(38,480)
Adjustments for increase in other operating receivables		(134,120)	-
Adjustments for increase / (decrease) in trade accounts payable		14,381	(34,236)
Adjustments for impairment losses and reversal of impairment losses recognised in profit or loss		21,370	-
Total adjustments to reconcile profit		(177,077)	(115,888)
Net cash flows used in operations		(109,242)	(81,047)
Interest received		88,724	43,172
Net cash flows used in operating activities		(20,518)	(37,875)
Cash flows from investing activities			
Purchase of other financial assets		-	25,500
Cash flows from investing activities		-	25,500
Net decrease in cash and cash equivalents		(20,518)	(12,375)
Cash and cash equivalents at beginning of the year		1,369,720	1,382,095
Cash and cash equivalents at end of the year	5	1,349,202	1,369,720

National Veterinary Clinicians Group

Financial Statements for the year ended 31 December 2023

Accounting Policies

1. General information

National Veterinary Clinicians Group ('the company') is in the promotion of the interest of veterinary clinicians.

The company is incorporated as a private company and domiciled in South Africa. The address of its registered office is 62 Herbert Baker Street, Groenkloof, Pretoria, Gauteng, 0181.

2. Basis of preparation and summary of significant accounting policies

The financial statements of National Veterinary Clinicians Group have been prepared in accordance with the IFRS for SMEs Accounting Standard as issued by the International Accounting Standards Board and the Companies Act of South Africa. The financial statements have been prepared under the historical cost convention, as modified by the revaluation of investment property, certain property, plant and equipment, biological assets and derivative financial instruments at fair value. They are presented in South African Rand.

The preparation of financial statements in conformity with the IFRS for SMEs Accounting Standard as issued by the International Accounting Standards Board requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 3.

The principal accounting policies applied in the preparation of these annual financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

2.1 Financial instruments

Trade and other receivables

Most sales are made on the basis of normal credit terms and the receivables do not bear interest. Where credit is extended beyond normal credit terms, receivables are measured at amortised cost using the effective interest method. At the end of each reporting period, the carrying amounts of trade and other receivables are reviewed to determine whether there is any objective evidence that the amounts are not recoverable. If so, an impairment loss is recognised immediately in profit or loss.

Trade and other receivables are classified as debt instruments and loan commitments at amortised cost.

Cash and cash equivalents

Cash and cash equivalents includes cash on hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are shown in current liabilities on the statement of financial position.

Trade and other payables

Trade payables are obligations on the basis of normal credit terms and do not bear interest.

2.2 Revenue

Revenue is measured at the fair value of the consideration received or receivable. Revenue is shown net of value-added tax, returns, rebates and discounts.

National Veterinary Clinicians Group

Financial Statements for the year ended 31 December 2023

Accounting Policies

Basis of preparation and summary of significant accounting policies continued...

Revenue from the sale of goods is recognised when:

- significant risks and rewards of ownership of the goods have been transferred to the buyer;
- the entity retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the entity; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

When the outcome of a transaction involving the rendering of services can be estimated reliably, revenue associated with the transaction is recognised by reference to the stage of completion of the transaction at the end of the reporting period. The outcome of a transaction can be estimated reliably when all the following conditions are satisfied:

- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the entity;
- the stage of completion of the transaction at the end of the reporting period can be measured reliably; and
- the costs incurred for the transaction and the costs to complete the transaction can be measured reliably.

When the outcome of transactions involving the rendering of services cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.

The stage of completion of a transaction may be determined by a variety of methods, depending on the nature of the transaction:

- surveys of work performed;
- services performed to date as a percentage of total services to be performed;
- the proportion that costs incurred to date bear to the estimated total costs of the transaction. Only costs that reflect services performed to date are included in costs incurred to date. Only costs that reflect services performed or to be performed are included in the estimated total costs of the transaction.

Interest income is recognised using the effective interest method.

Rental income from investment property that is leased to a third party under an operating lease is recognised in the statement of comprehensive income on a straight-line basis over the lease term and is included in 'other income'.

Dividend income is recognised when the company's right to receive payment has been established and is shown as 'finance income'.

Royalties are recognised on an accrual basis in accordance with the substance of the relevant agreement.

3. Critical accounting estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

National Veterinary Clinicians Group

Financial Statements for the year ended 31 December 2023

Notes to the Financial Statements

Figures in R

2023

2022

4. Trade and other receivables

Trade and other receivables comprise:

Trade receivables	26,504	57,890
Sundry debtors : Vetlink	50,026	-
Prepaid expenses	84,094	-
Deposits	32,690	32,690
	<u>193,314</u>	<u>90,580</u>

5. Cash and cash equivalents

Detail of cash and cash equivalent balances

Bank balances

FNB Gold Business account : 50920007800	142,086	123,102
FNB Money on Call account : 62058822290	893,212	957,176
FNB 32 Day Interest Plus account : 72092015404	147,500	136,321
FNB 32 Day Notice Deposit account : 74059636017	166,404	153,121
Total	<u>1,349,202</u>	<u>1,369,720</u>

6. Trade and other payables

Trade and other payables comprise:

	2023	2022		
Trade payables			138,482	124,101
Audit fee 2021	12,852	12,852		
Audit fee 2022	-	14,100		
Audit fee 2023	15,230	-		
Refund - Vetsfocus	-	-		
Income received in advance	-	17,121		
Vetlink - Website hosting and telephone	-	13,409		
Admin fees - Madaleen Schultheiss	110,400	51,600		
Vetlink CC	-	-		
Refund - Netflorist	-	529		
Refund - WSAVA Membership	-	14,490		
	<u>138,482</u>	<u>124,101</u>		

7. Revenue

Revenue comprises:

Membership fees	123,410	148,977
NVCG Congress income 2023	50,026	-
Reimbursement of expenses	-	18,628
SAVA Pre Congress Income	-	1,750
Total revenue	<u>173,436</u>	<u>169,355</u>

National Veterinary Clinicians Group

Annual Financial Statements for the year ended 31 December 2023

Detailed Income Statement

Figures in R

Note

2023

2022

Revenue

7

Membership fees	123,410	148,977
NVCG Congress income 2023	50,026	-
Reimbursement of expenses	-	18,628
SAVA Pre Congress Income	-	1,750
	173,436	169,355

Other expenses

Accounting fees	(4,140)	(3,219)
Admin and selling expenses	(110,400)	(108,381)
Auditors remuneration - Fees	(15,230)	(14,100)
Bad debts	(21,370)	-
Bank charges	(1,413)	(1,062)
Telecommunication	(8,464)	-
Website	-	(4,945)
World Veterinary Congress / WSAVA	(33,308)	(45,979)
	(194,325)	(177,686)

Loss from operating activities

(20,889)

(8,331)

Finance income

Interest received	88,724	43,172
-------------------	--------	--------

Profit for the year

67,835

34,841